Fujirebio Acquires Rights to Ovarian Tumor Markers

(FDI, Malvern, PA, USA) from Pacific Northwest Research Institute (PNRI, Seattle, WA, USA).

Fujirebio has developed a serum-based assay, CA125II, for ovarian cancer detection. Research findings show that combining the three ovarian cancer markers may result in a greatly improved diagnostic capability, particularly for the detection of early stage disease, says Fujirebio. Recent studies suggest that combining several select tumor markers, possibly in a multiplex mode, could result in a more sensitive and specific assay for the early diagnosis of ovarian cancer.

"Multiplex assays are a novel development in the area of cancer detection,” said Daniel O'Shannessy, Ph.D., chief scientific officer of FDI. "They are currently used in a limited capacity, but have the potential to profoundly change diagnostics. Combining mesothelin and HE4 with CA125II has a potentiating effect on the diagnostic ability of CA125II.”

PNRI is a nonprofit biomedical and clinical research laboratory, focused on the pathogenesis and prevention of disease, especially diabetes and cancer.




Related Links:
Pacific Northwest Research Institute
Fujirebio, Inc.